CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: While our findings suggest the potential use of RXRA agonists in combination with IM in eliminating CML CD34+in-vitro and sensitizing CML bulk cells highly resistant to IM (IC50 > 53uM), a more robust in-vivo model to evaluate the therapeutic efficacy of this combination and anti-leukemogenic potential RXRA has on CML LSCs is needed.